Effect Of SLC35F2 Expression On Cell Viability And Drug Sensitivity In Non-small Cell Lung Cancer Cells

Studies have shown that the human solute carrier family 35 member F2(SLC35F2)as a member of the SLC solute family is abnormally expressed in malignant tumors such as lung cancer and neuroblastoma,and can directly or indirectly regulate the occurrence and development of tumors.It was found that the expression of SLC35F2 gene in human non-small cell lung cancer(NSCLC)tissues is high,and the transcription level is related to tumor stage,which has significant prognostic value for patients.Simultaneous expression level and drug transport activity of SLC35F2 in tumor cells and chemotherapy The sensitivity of the drug is related.In this study,the effects of SLC35F2 expression levels on tumor biological function and chemotherapeutic drug sensitivity were studied in in vitro lung adenocarcinoma cell line A549,95 D.OBJECTIVE: To establish a stable SLC35F2 low-and high-expression non-small cell lung cancer cell line A549 and 95 D in vitro lung adenocarcinoma cell lines,and to study the sensitivity of SLC35F2 expression level to tumor biological function and chemotherapeutic drugs through a series of cell functional experiments.influences.Experimental methods: 1 Construction of SLC35F2 low expression and high expression of non-small cell lung cancer cell lines A549 and 95 D cell lines;2 through MTT,cell cycle and apoptosis,Transwell chamber experiments,scratch experiments,cloning experimental methods to study the expression level of SLC35F2 The effect of cancer cell proliferation,apoptosis,migration and invasion ability;3 The optimal concentration of paclitaxel and YM155 was determined by MTT assay;4 The effect of SLC35F2 on the drug sensitivity of paclitaxel and YM155 was studied by in vitro functional assay.Experimental results: down-regulation of SLC35F2 expression,MTT assay A549 cell control group OD490 value was 0.817,experimental group OD490 value 0.514,cell proliferation ability decreased(P = 1.55 * 10-9;p < 0.001);clone experiment number of clone control 168,experimental group 81,the number of clonal cells decreased(P-value=0.00002;p<0.001);the number of cell apoptosis was 4.06 in the control group,and the number of apoptosis in the experimental group was 6.3(P-value=0.00056;P<0.001)The value of the cell control group in the G1 phase was 52.76,the value in the experimental group was 65.74,and the number of cells in the G1 phase increased(P-value=9.7*10-5;p<0.001),and the number of cells in the S phase decreased(P-value=0.001;p <0.001);In the Transwell experiment,the cell migration control value was 244,the experimental group value was 9,and the cell mobility was decreased(P-value = 2.68 * 10-6;p < 0.001);After paclitaxel-treated A549 cells were down-regulated in SLC35F2,the number of cells in the G1 phase was 78.37,the experimental group was 39.03,and the cells in the G1 phase were increased(P-value=0.00087;p<0.001).8.7,the experimental group value of 14.53,the cell phase in the S phase decreased(P-value = 0.00589;p < 0.001),the cell proliferation ability decreased;YM155 treated A549 cells were down-regulated in SLC35F2,the number of cloned cells in the control group 58,the experimental group 134,the number of clones increased(P-value=7*10-5;p<0.001);the number of apoptosis decreased(P-value=4.72*10-6;p<0.001);Conclusion: The down-regulation of SLC35F2 is positively correlated with the function of non-small cell lung cancer cells;it also reduces the sensitivity of paclitaxel and YM155.